Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management ...
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...
Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See more on REPL stock here.
Every time Rosalie publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
HENLEY-IN-ARDEN, United Kingdom and DALLAS, Jan. 10, 2020 /PRNewswire/ -- Global retail IT consultancy and technology firm, REPL Group has successfully rolled out JDA Workforce Management to help ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Replimune Group, Inc. REPL announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ BMY blockbuster ...
Repl.it is a start-up whose technology lets software engineers quickly write and ship code from a web browser. The start-up has raised a $4.5 million round of initial funding led by Andreessen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results